Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
coliprotec
- Development stage
- Unknown
- Lead developer
- Prevtec Microbia
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
**Coliprotec** is a live oral vaccine for pigs, composed of non-pathogenic strains of *Escherichia coli*: O8:K87 (F4ac) alone (Coliprotec F4) or combined with O141:K94 (F18ac) in the bivalent form (Coliprotec F4/F18)[1][3][5][7]. It is used for the active immunization of pigs from at least 18 days of age to reduce the incidence of moderate to severe post-weaning diarrhea (PWD) caused by enterotoxigenic F4-positive or F18-positive *E. coli* and to decrease *E. coli* colonization and fecal shedding[1][5][7]. Upon oral administration, the live vaccine colonizes the gut, inducing mucosal immunity against the corresponding *E. coli* fimbrial antigens. The F4 or F18 fimbriae enable adhesion to pig intestinal mucosa, which is necessary for the initiation of infection; the vaccine preempts this via competitive exclusion and immune stimulation[3][11]. The onset of immunity is 7 days post-vaccination, with a duration of up to 21 days[1][5].
- Brand names
- ColiprotecColiprotec F4Coliprotec F4/F18
02
Targets
F18ab (Escherichia coli F18ab fimbriae)F4 (F4 fimbriae)
Beyond the preview
Go deeper on coliprotec.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on coliprotec.